Merck MRK
NYSE MRK
$152.55 +3.56 (+2.39%)
At close: Aug 21, 2026 · 4:01 PM EDT

Merck (MRK) Amortizatization of Intangibles (2020 - 2026)

Merck (MRK) posted quarterly Amortizatization of Intangibles of $931.0 million for Q1 2026, up 55.95% year-over-year from $597.0 million in Q1 2025, and down 4.32% quarter-over-quarter from $973.0 million in Q4 2025.

Merck (MRK) Amortizatization of Intangibles (2020 - 2026) Analysis & Trends

Merck (MRK) has reported Amortizatization of Intangibles for 7 consecutive years, with $931.0 million the latest figure, recorded in Q1 2026.

  • In Q1 2026, Amortizatization of Intangibles rose 55.95% year-over-year to $931.0 million; the TTM figure through Mar 2026 stood at $3.1 billion (up 24.18% YoY), while the FY2025 annual figure was $2.8 billion, up 16.62% from the prior year.
  • Amortizatization of Intangibles slipped to $931.0 million in Q1 2026 per MRK's latest filing, from $973.0 million in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $973.0 million in Q4 2025 and bottomed at $460.0 million in Q3 2022.
  • Historically, Amortizatization of Intangibles has averaged $602.8 million across 5 years, with a median of $597.0 million in 2025.
  • Annual changes were most pronounced in 2023 — Amortizatization of Intangibles declined 22.32% — and 2026, when it soared 55.95%.
  • Merck's Amortizatization of Intangibles stood at $462.0 million in 2022, then changed by 0.0% to $462.0 million in 2023, then surged by 46.1% to $675.0 million in 2024, then soared by 44.15% to $973.0 million in 2025, then slipped by 4.32% to $931.0 million in 2026.
  • Business Quant data shows MRK's Amortizatization of Intangibles at $931.0 million in Q1 2026, $973.0 million in Q4 2025, and $623.0 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Amortizatization of Intangibles (Qtr)
1 Johnson & Johnson 652.20 Bn 631.44 Bn 17.26 Bn -
2 AbbVie 469.51 Bn 462.94 Bn 12.70 Bn -
3 Merck 376.81 Bn 369.67 Bn 12.21 Bn 984.00 Mn
4 Novartis Ag 303.04 Bn 295.35 Bn 11.24 Bn -
5 Astrazeneca 257.61 Bn 252.71 Bn 12.86 Bn -
6 Amgen 237.37 Bn 223.38 Bn 7.24 Bn -
7 Gilead Sciences 181.73 Bn 178.55 Bn 6.22 Bn 600.00 Mn
8 Pfizer 159.66 Bn 147.96 Bn 10.94 Bn -
9 Gsk 106.24 Bn 102.07 Bn 8.24 Bn -
10 Sanofi 55.07 Bn 47.69 Bn 10.79 Bn -

Historic Data

Download Data
DateValue
Jun 30, 2026 984.00 Mn
Jun 30, 2026 984.00 Mn
Mar 31, 2026 931.00 Mn
Mar 31, 2026 931.00 Mn
Dec 31, 2025 973.00 Mn
Dec 31, 2025 973.00 Mn
Sep 30, 2025 623.00 Mn
Sep 30, 2025 623.00 Mn
Jun 30, 2025 601.00 Mn
Jun 30, 2025 601.00 Mn
Mar 31, 2025 597.00 Mn
Mar 31, 2025 597.00 Mn
Dec 31, 2024 675.00 Mn
Dec 31, 2024 675.00 Mn
Sep 30, 2024 633.00 Mn
Sep 30, 2024 633.00 Mn
Jun 30, 2024 614.00 Mn
Jun 30, 2024 614.00 Mn
Mar 31, 2024 473.00 Mn
Mar 31, 2024 473.00 Mn